StockData
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. (MIRM) stock

MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30
$93.99+0.66 (+0.71%)

Close on Nov 13, 2026Market cap $6.10BP/E –Yield –

Mirum Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Mirum Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$808.02M. For fiscal 2025 it was $2.11M. The highest annual figure on record is $2.11M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.11M–
FY2024Dec 31, 2024-$63.98M–
FY2023Dec 31, 2023-$98.33M–
FY2022Dec 31, 2022-$127.98M–
FY2021Dec 31, 2021-$172.82M–
FY2020Dec 31, 2020-$103.99M–
FY2019Dec 31, 2019-$54.60M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.60M-3436.6%
Q1 FY2026Mar 31, 2026-$782.59M–
Q4 FY2025Dec 31, 2025$1.51M–
Q3 FY2025Sep 30, 2025$8.67M–
Q2 FY2025Jun 30, 2025$1.07M–
Q1 FY2025Mar 31, 2025-$9.13M–
Q4 FY2024Dec 31, 2024-$18.17M–
Q3 FY2024Sep 30, 2024-$6.63M–
Q2 FY2024Jun 30, 2024-$18.38M–
Q1 FY2024Mar 31, 2024-$20.80M–
Q4 FY2023Dec 31, 2023-$27.09M–
Q3 FY2023Sep 30, 2023-$22.49M–
Q4 FY2022Dec 31, 2022-$32.96M–
Q3 FY2022Sep 30, 2022-$31.79M–
Q2 FY2022Jun 30, 2022-$30.84M–
Q1 FY2022Mar 31, 2022-$32.39M–
Q4 FY2021Dec 31, 2021-$45.23M–
Q3 FY2021Sep 30, 2021-$42.74M–
Q2 FY2021Jun 30, 2021-$37.32M–
Q1 FY2021Mar 31, 2021-$47.52M–
Q4 FY2020Dec 31, 2020-$36.87M–
Q3 FY2020Sep 30, 2020-$21.64M–
Q2 FY2020Jun 30, 2020-$23.53M–
Q1 FY2020Mar 31, 2020-$21.96M–
Q4 FY2019Dec 31, 2019-$18.60M–
Q3 FY2019Sep 30, 2019-$15.83M–
Q2 FY2019Jun 30, 2019-$13.99M–
Q1 FY2019Mar 31, 2019-$6.18M–

More Mirum Pharmaceuticals figures

See a number that looks wrong?